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Besides the demand for higher sensitivity, the speciﬁcity of cfDNA
measurements faces even more serious challenges. Cancer-associated
mutations are thought to be restricted to cancer patients. However,
Fernandez-Cuesta et al. observed cfDNA TP53-mutated fragments in
11.4% of 123 matched non-cancer controls. Acknowledging the poten-
tial for bias in the selection of controls (such as differential performanceDetection of cancer by analysis of circulating cell-free DNA (cfDNA)
has received enormous attention over the past years (Alix-Panabieres
and Pantel, 2016). cfDNA is released into the blood circulation by apo-
ptotic and necrotic cells, and cancer patients have increased concentra-
tions of cfDNA (Schwarzenbach et al., 2011). With the development of
novel technologies it is now possible to detect tumor-associated muta-
tions on cfDNA and monitor the evolution of cancer progression in pa-
tients (Bettegowda et al., 2014). However, the detection of very low
amounts of circulating tumor-derived DNA (ctDNA) in blood samples
from early stage cancer patients is still a challenge. ctDNAwas revealed
in only 48–73% of patients with localized cancers including lung cancer
(Bettegowda et al., 2014; Newman et al., 2014).
In this issue of EBioMedicine, Fernandez-Cuesta et al. (2016) have
assessed cfDNA from patients with small-cell lung cancer (SCLC) for
TP53 mutations known to occur in the majority of SCLC cases (George
et al., 2015). The analysis of cfDNA using an assay speciﬁcally designed
to accurately detect variants at very low allelic fractions revealed TP53
mutations in 49% of SCLC patients and, most importantly for cancer de-
tection, in 35.7% of early-stage cases. This incidence in early stage SCLC
matches those reported for other cancer types and suggests that early-
stage tumors might shed only minute amounts of DNA into the circula-
tion. Thus, TP53mutations alone have limited sensitivity as marker for
detection of early SCLC. So far, it remains to be investigated whether
more sensitive technologies or the addition (or combinations) of other
cancer-speciﬁc mutations will increase the sensitivity of liquid biopsy.
Moreover, larger plasma volumes, and across repeated time points,
might be required for early cancer detection, far beyond the “one
blood drop” promise. The ctDNA concentration in early-stage lung can-
cer patients can be as low as one genome equivalent in 5 ml blood
(Newman et al., 2016). The need for larger blood volumes in earlym.2016.06.032.
en access article under the CC BY-NCstage cancer patients has been already realized for CTC-based liquid bi-
opsies (Alix-Panabieres and Pantel, 2014).
in QC criteria or cfDNA amount, between cases and controls), they
screened a second series of 102 non-cancer controls, and found a com-
parable proportion of TP53mutations (13 TP53mutations in 11 controls,
10.8%). Cancer cases and controlswerematched for age aswell as tobac-
co and alcohol consumption. The present results are consistent with re-
cent ﬁndings of Krimmel et al. (2016), demonstrating very low levels of
TP53mutations in the peritoneal ﬂuid and peripheral blood of women
with benign ovarian lesions. Previously, Genovese et al. (2014) demon-
strated that leukemia-associated mutations also occur with increasing
age, and although posing a statistically signiﬁcant risk to develop leuke-
mia, most individuals (N90%) who tested “positive” never developed
leukemia during their lifetime. Clonal hematopoiesis with somatic mu-
tations was observed in 10% of persons older than 65 years of age and
the absolute risk of conversion from clonal hematopoiesis to hemato-
logic cancer was low (Genovese et al., 2014). Fernandez-Cuesta et al.
also observed two TP53 mutations in one SCLC patient, one originating
from leukocytes, which adds another layer of complexity.
In conclusion, further improvements are required to reach an ac-
ceptable sensitivity and speciﬁcity for early cancer detection. The pres-
ence of cancer-associated mutations on cfDNA might not necessarily
indicate that the individual tested has already cancer or will develop
cancer in her/his life time but it might induce substantial anxiety and
extensive diagnostic procedures with health risks like radiation in CT
scans. Cohort studies focusing on patients at high risk to develop cancer
have been successful for CTCs as liquid biomarkers (Alix-Panabieres and
Pantel, 2016). Extensive research is required to identify possible combi-
nations of cancer-speciﬁc mutations and deﬁne quantitative potential
thresholds to avoid over-diagnosis. Moreover, the interpretation of
DNA screening results of leukocytes (or other normal cells) as
“germline” mutations, which is current practice in disease research
studies focusing on genetic predisposition,might be corrupted in ageing
individuals (e.g., prostate cancer patients) by somatic background mu-
tations in normal cells. Standardization and validation of cfDNA assays
are important issues realized by the current EU/IMI consortium CAN-
CER-ID (www.cancer-id.eu).-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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